- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 40/42 - Antigènes associés au cancer
Détention brevets de la classe A61K 40/42
Brevets de cette classe: 2264
Historique des publications depuis 10 ans
|
6
|
11
|
21
|
58
|
149
|
240
|
115
|
79
|
827
|
388
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Trustees of the University of Pennsylvania | 4406 |
60 |
| The Regents of the University of California | 20574 |
51 |
| Memorial Sloan-Kettering Cancer Center | 2006 |
43 |
| Kite Pharma, Inc. | 437 |
36 |
| Iovance Biotherapeutics, Inc. | 366 |
33 |
| Juno Therapeutics, Inc. | 488 |
31 |
| Board of Regents, The University of Texas System | 6050 |
30 |
| Immunitybio, Inc. | 494 |
29 |
| Novartis AG | 10327 |
27 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2973 |
26 |
| Dana-Farber Cancer Institute, Inc. | 2648 |
25 |
| The Board of Trustees of the Leland Stanford Junior University | 6600 |
24 |
| Autolus Limited | 266 |
24 |
| City of Hope | 1017 |
24 |
| The General Hospital Corporation | 4827 |
22 |
| Regeneron Pharmaceuticals, Inc. | 4618 |
22 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1010 |
21 |
| Fred Hutchinson Cancer Center | 465 |
21 |
| Allogene Therapeutics, Inc. | 161 |
19 |
| Immatics Biotechnologies GmbH | 1117 |
18 |
| Autres propriétaires | 1678 |